Formerly at IGM Biosciences, Godfrey joins Janux as it prepares to enter clinical trials with its T cell engager therapies.
San Diego-based Janux Therapeutics recently announced the appointment of Wayne Godfrey, M.D., as Chief Medical Officer, effective June 1, 2021.
Godfrey was previously VP of Clinical Development at IGM Biosciences, which is developing engineered IgM antibody therapies for oncology and infectious disease indications. Before that, he was Senior Director, Clinical Development at Gilead subsidiary Kite Pharma.
“I am impressed with the thoughtful modular design of the TRACTr platform technology and Janux’s current drug product candidates, which are designed to deliver highly tumor-specific activation of T cell activity while incorporating crossover pharmacokinetics to minimize healthy tissue toxicity,” said Godfrey in a press release.
Last year the company announced a $1 billion partnership with Merck, using Janux’s Tumor Activated T Cell Engager (TRACTr) technology to engineer new drug candidates directed against oncology targets chosen by Merck.